梯瓦製藥工業有限公司

TEVA stock represents ownership in Teva Pharmaceutical Industries Ltd., a multinational pharmaceutical company. The stock trades on the New York Stock Exchange and on the Tel Aviv Stock Exchange under the ticker TEVA. As an equity security, it gives investors exposure to Teva's generic and specialty medicine business. Its price reflects supply and demand for shares, company performance, and broader market conditions. For current quotes and details, see the TEVA data displayed on this page.

Teva operates in the pharmaceutical industry, with a focus on generic and specialty medicines. It develops, manufactures, and markets products across multiple therapeutic areas, including central nervous system and respiratory treatments. The company is also known for its generic drug portfolio and its role in the global healthcare supply chain. Because it competes in a highly regulated sector, industry trends such as drug pricing and patent expirations can influence TEVA's business and stock.

Valuation for TEVA generally involves comparing its share price to financial fundamentals such as earnings, revenue, and cash flow. Metrics like the price-to-earnings ratio, price-to-sales ratio, and enterprise value multiples can be useful, especially because pharmaceutical firms often carry debt and face patent cliffs. Comparing TEVA's valuation to peers and its own historical averages provides context. The latest valuation metrics for TEVA are shown on this page and should be reviewed alongside the company's financial reports.

TEVA stock can be influenced by company-specific developments such as drug approvals, patent litigation, generic competition, and changes in revenue or profitability. Broader factors include healthcare regulation, drug pricing policies, interest rates, and currency movements, since Teva operates globally. Manufacturing disruptions or legal matters can also affect the shares. Because these variables change over time, checking the latest TEVA news and financial data on this page is important for understanding current influences.

Key risks for TEVA include significant debt levels, exposure to generic drug price erosion, patent expirations, and legal or regulatory challenges such as litigation and compliance issues. Currency fluctuations and global economic conditions can also affect results because Teva operates in many markets. Competition from other generic manufacturers and reliance on key products add further uncertainty. These risks can pressure the stock and financial performance, so they should be considered alongside the latest TEVA disclosures on this page.

Earnings information for TEVA is typically available through the company's investor relations website, where quarterly and annual reports, press releases, and earnings call transcripts are posted. Major financial news outlets and regulatory filings with the U.S. Securities and Exchange Commission also provide earnings details. On this page, you can find the latest TEVA earnings data and related financial highlights. Reviewing revenue, profit, and guidance trends helps investors assess the company's performance over time.